Ideaya Biosciences is trading at $39.00, up +7.97%, in pre-market on October 23, 2026, amid updated IDE849 clinical results, the clearest available company-specific catalyst.
- Updated Phase 1 results reported promising anti-tumor activity and preliminary overall-survival results in relapsed small-cell lung cancer and neuroendocrine carcinomas.
- The data were presented at ESMO 2026.
- The release did not attribute the share-price move to the news; the supplied market context was broadly weaker and does not explain the rise.